Status:
RECRUITING
Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Hematopoietic and Lymphoid Cell Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
This study collects information on outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies. Collecting information from patients before, during, and after r...
Detailed Description
PRIMARY OBJECTIVE: I. Record clinical outcomes of patients with hematologic malignancies receiving standard-of-care chimeric antigen receptor therapy (CAR-T) nd/or standard-of- care bispecific therap...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age 18 years or older
- Treatment with or intention to treat with radiation therapy, standard-of-care CAR-T cell therapy and/or standard-of-care bispecific therapy, within a 90 day window for a hematologic malignancy
Exclusion
Key Trial Info
Start Date :
April 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 14 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04888338
Start Date
April 10 2021
End Date
November 14 2026
Last Update
October 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030